A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.10, Iss.8, 2001-08, pp. : 1559-1566

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of standard triple therapy, sequential therapy and moxifloxacin‐based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates

Journal of Digestive Diseases, Vol. 15, Iss. 9, 2014-09 ,pp. : 508-513

John Wiley & Sons Inc

Access to resources Recommend Favorite

Potential of fumarate reductase as a novel therapeutic target in Helicobacter pylori infection

By Ge Zhongming

Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 2, 2002-04 ,pp. : 135-146

Informa Healthcare

Access to resources Recommend Favorite

Evolving therapy for Helicobacter pylori infection

By Zullo Angelo Hassan Cesare Campo Salvatore MA Morini Sergio

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 10, 2004-10 ,pp. : 1453-1464

Informa Healthcare

Access to resources Recommend Favorite

Novel therapeutic targets in Helicobacter pylori

By Loughlin Michael F

Expert Opinion on Therapeutic Targets, Vol. 7, Iss. 6, 2003-12 ,pp. : 725-735

Informa Healthcare

Access to resources Recommend Favorite

Adding bovine lactoferrin to triple therapy in patients with Helicobacter pylori infection increases eradication rates

Inpharma, Vol. 1, Iss. 1540, 2006-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite